Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Int J Clin Oncol ; 28(4): 587-591, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36662363

ABSTRACT

BACKGROUND: To investigate perinatal outcomes in pregnancy after high-dose medroxyprogesterone acetate (MPA) therapy for early stage endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) and to determine whether pregnancy after MPA therapy is at a higher risk of placenta accreta. METHODS: Data of 51 pregnancies in 46 women who received MPA therapy for EC or AEH and delivered after 22 weeks of gestation at Keio University Hospital were reviewed. A retrospective matched case-control study was performed to determine the risk of placenta accreta in pregnancy after MPA therapy compared with singleton pregnancies without any history of maternal malignancy treatments. RESULTS: The incidence of placenta accreta was higher in the MPA group than in the control group (15.7 vs. 0%, p = 0.0058). However, no differences in other perinatal outcomes were observed between groups. While gestational weeks at delivery in the MPA group were later than those in the control group (p = 0.0058), no difference in the incidence of preterm delivery was recorded between groups. In the MPA therapy group, the number of patients who underwent ≥ 6 dilation and curettage (D&C) was higher in the placenta accreta group than in the non-placenta accreta group (50.0 vs. 14.0%, p = 0.018). Patients with ≥ 6 D&Cs demonstrated a 6.0-fold increased risk of placenta accreta (p = 0.043, 95% CI 1.05-34.1) than those receiving ≤ 3 D&Cs. CONCLUSION: Pregnancy after MPA therapy is associated with a high risk of placenta accreta. In cases in which the frequency of D&C is high, placenta accreta should be considered.


Subject(s)
Endometrial Hyperplasia , Endometrial Neoplasms , Hospitals , Medroxyprogesterone Acetate , Neoplasm Staging , Placenta Accreta , Female , Humans , Pregnancy , Dilatation and Curettage , Endometrial Hyperplasia/drug therapy , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/pathology , Medroxyprogesterone Acetate/adverse effects , Medroxyprogesterone Acetate/therapeutic use , Placenta Accreta/chemically induced , Placenta Accreta/etiology , Premature Birth , Retrospective Studies , Obstetrics , Adult , Middle Aged
2.
Int J Gynaecol Obstet ; 164(1): 108-114, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37340875

ABSTRACT

OBJECTIVE: The authors aimed to investigate the prevalence of pregnancy and obstetric outcomes in patients who underwent radical trachelectomy (RT) for early-stage cervical cancer in the Kanto area, Japan. METHOD: A survey among 113 perinatal centers affiliated with the Kanto Society of Obstetrics and Gynecology was conducted to investigate their experience in managing pregnancies following RT, between 2010 and 2020. The association between preterm delivery (before 34 gestational weeks) and a midtrimester short cervix (<13 mm) was evaluated. RESULTS: The authors retrospectively collected maternal and perinatal data from 13 hospitals. There were 135 pregnancies among 115 women following RT. Of the 135 pregnancies, 32 were miscarriages (<12 gestational weeks: n = 22; >12 gestational weeks: n = 10), and 103 were delivered after 22 gestational weeks. The incidences of preterm delivery before 28 and 34 gestational weeks were 8.7% and 30.1%, respectively. A midtrimester short residual cervix was associated with preterm delivery (P = 0.046). CONCLUSION: Since more than 100 pregnancies were recorded after RT in the Kanto area, many physicians had more opportunities to manage pregnancy after RT. Pregnancy following RT is associated with increased risk of preterm delivery, and midtrimester short residual cervix is a good predictor of preterm delivery.


Subject(s)
Premature Birth , Trachelectomy , Uterine Cervical Neoplasms , Pregnancy , Infant, Newborn , Female , Humans , Pregnancy Outcome , Cervix Uteri/surgery , Trachelectomy/adverse effects , Premature Birth/epidemiology , Premature Birth/etiology , Uterine Cervical Neoplasms/surgery , Uterine Cervical Neoplasms/etiology , Retrospective Studies , Japan/epidemiology
3.
J Dev Orig Health Dis ; 14(5): 584-590, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37699750

ABSTRACT

Late preterm (LP, born between 34 0/7 and 36 6/7 weeks of gestation) infants may experience several adverse outcomes, similar to those experienced by low birthweight (LBW, birthweight <2500 g) infants. However, while LP infants are often born with LBW, the association between LP and LBW remains unknown. This study aimed to investigate LBW rate and independent risk factors for LBW in LP singleton neonates. We retrospectively analyzed data of LP singleton neonates, born between 2013 and 2017, from the Japan Society of Obstetrics and Gynecology Successive Pregnancy Birth Registry System. The exclusion criteria included stillbirths and infants with missing data. Logistic regression analyses were performed to investigate maternal and perinatal factors associated with LBW in LP singletons. LBW was observed in 62.5% (n = 35,113) of 56,160 LP singleton births. In the multiple logistic regression analysis, LBW in LP neonates was independently associated with modifiable maternal factors, including pre-pregnancy underweight, inadequate gestational weight gain, and smoking during pregnancy, as well as non-modifiable factors, including younger maternal age, nulliparity, hypertensive disorder of pregnancy, preeclampsia, cesarean section delivery, and female offspring. According to the Japanese pregnancy birth registry data, more than half of LP neonates were LBW. We previously discussed the issue of LBW regarding infants with different backgrounds, as there are many different causes of LBW. Several risk factors should be subdivided and considered for the risk of LP and LBW.


Subject(s)
Cesarean Section , Premature Birth , Infant, Newborn , Pregnancy , Female , Humans , Japan/epidemiology , Birth Weight , Retrospective Studies , Cesarean Section/adverse effects , Routinely Collected Health Data , Risk Factors , Parity , Premature Birth/epidemiology , Premature Birth/etiology
SELECTION OF CITATIONS
SEARCH DETAIL